Non-alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease (NAFLD) is a condition where excess fat builds up in the liver without alcohol consumption, potentially leading to inflammation and liver damage.
Efruxifermin for Non-Cirrhotic NASH/MASH
We are studying whether Efruxifermin can improve liver health and reduce fibrosis in people with Non-Cirrhotic NASH or MASH. Participants will be compared to those receiving a placebo to assess safety and effectiveness.
1-2 years11-15 visitsConfirmation phase (III)Investigational MedicinesInjectionEndocrinologyHepatology
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Hepatic Fibrosis
Hepatic Fibrosis is a condition characterized by the accumulation of scar tissue in the liver, often resulting from chronic liver diseases, which can lead to liver dysfunction.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 80 years old?
- Do you have Type 2 diabetes or metabolic syndrome (which includes obesity, high cholesterol, high blood pressure, or high blood sugar)?
- Are you currently pregnant or breastfeeding?
- Have you had significant weight loss of more than 10% in the last 90 days?
- Do you have cirrhosis (severe liver disease) or a history of liver transplantation?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Efruxifermin
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Centre Hospitalier Universitaire D'Angers
Hépato-Gastroentérologie
Angers, France
Hopital De La Croix Rousse
Hépato-Gastroentérologie
Caluire-et-Cuire, France
Hopital Beaujon
Hepatologie
Clichy, France
Sponsor: Akero Therapeutics Inc.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.